This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Hold on to Myriad Genetics (MYGN) for Now
by Zacks Equity Research
Investors are optimistic about Myriad Genetics (MYGN), given robust volume growth for GeneSight and prenatal testing.
5 Stocks With Upgraded Broker Ratings for Attractive Returns
by Swayta Shah
It is advisable to follow broker rating upgrades for robust returns. Hence, we pick Boston Beer (SAM), Williams-Sonoma (WSM), Cerner (CERN), PNM Resources (PNM) and Sonoco (SON) as these witness rating upgrades.
Phirbo's (PAHC) Rising Costs, Currency Headwind Ail Growth
by Zacks Equity Research
Though Phirbo (PAHC) has raised prices on selective products, these increases do not fully compensate for the higher cost of freight and labor materials.
Here's Why You Should Hold on to National Vision (EYE) for Now
by Zacks Equity Research
Investors are optimistic about National Vision (EYE), given new store growth for America's Best and Eyeglass World brands.
Here's Why You Should Retain UnitedHealth Group (UNH) Now
by Zacks Equity Research
UnitedHealth Group (UNH) is well-poised for growth on the back of solid top-line growth, expansion of service offerings through UnitedHealthcare and Optum units, and adequate cash flows.
Here's Why You Should Invest in Abbott (ABT) Stock Right Now
by Zacks Equity Research
Riding on current business growth and bullish near-term prospects, Abbott (ABT) is worth investing in for now.
Thermo Fisher (TMO) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Strength in end markets and significant contribution from COVID-response related revenues are driving Thermo Fisher's (TMO) top line.
Omnicell (OMCL) Closes ReCept Holdings Acquisition Deal
by Zacks Equity Research
Omnicell's (OMCL) completed buyout of the renowned specialty pharmacy management services provider is likely to bolster its Advanced Services offering.
Neogen (NEOG) Q2 Earnings Lag Estimates, Revenues Surpass
by Zacks Equity Research
Robust segmental performance and contributions from StandGuard & Soleris product lines drove the top line for Neogen (NEOG) in the second quarter of fiscal 2022.
Is Oracle's (ORCL) Cloud Strategy Headed the Right Direction?
by Zacks Equity Research
Oracle's (ORCL) performance is gaining from momentum across the cloud business, driven by the strong uptake of OCI services and Autonomous Database offerings.
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors are optimistic about ResMed's (RMD) strong sales in its mask product offering and growing uptake of its digital health solutions.
Here's Why You Should Invest in Bio-Rad (BIO) Stock Now
by Zacks Equity Research
Investors are optimistic about Bio-Rad (BIO) owing to robust segmental performances and a rebound in non-COVID businesses.
Zacks.com featured highlights include: Cerner, Dorman Products and AvalonBay Communities
by Zacks Equity Research
Zacks.com featured highlights include: Cerner, Dorman Products and AvalonBay Communities
Edwards Lifesciences (EW) at 52-Week High: What's Driving It?
by Zacks Equity Research
Robust performance across the Critical Care and TAVR businesses is driving the top line for Edwards Lifesciences (EW).
Forget Zimmer Biomet (ZBH), Buy These 3 Medical Devices Stocks
by Urmimala Biswas
With orthopedic stocks like Zimmer Biomet (ZBH) are grappling with several issues, it is wise to invest in medical device stocks like TMO, NEOG and CERN instead for 2022.
How Oracle's (ORCL) Cerner Buyout Could Affect its Ratings
by Zacks Equity Research
Oracle's (ORCL) debt profile could further deteriorate if the company takes up more debt to finance Cerner acquisition and that could lead to possible rating downgrades, noted Bloomberg.
How Microsoft's (MSFT) Nuance Buyout Fits Its Business Strategy
by Zacks Equity Research
The planned takeover of Nuance is likely to bolster Microsoft's (MSFT) position in the rewarding healthcare domain.
3 Solid Stocks to Invest in for Remarkable Earnings Acceleration
by Tirthankar Chakraborty
Cerner (CERN), Dorman Products (DORM) & AvalonBay Communities (AVB) at present flaunt superb earnings acceleration. This makes them compelling buys.
CERN vs. OMCL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CERN vs. OMCL: Which Stock Is the Better Value Option?
Cerner's (CERN) Acquisition by Oracle to Boost Patient Outcome
by Zacks Equity Research
Cerner's (CERN) buyout is likely to aid in growing its community presence as well as improve patient outcomes.
Oracle (ORCL) to Acquire Cerner for $28B in Cash, Shares Fall
by Zacks Equity Research
Oracle's (ORCL) takeover of Cerner Corporation (CERN) is expected to bolster the company's position in the lucrative healthcare domain.
Company News for Dec 20, 2021
by Zacks Equity Research
Companies in the news are: WGO, FDX, CERN, EPAY
Here's Why Oracle (ORCL) Could be Targeting Cerner Corp
by Zacks Equity Research
Oracle (ORCL) is reportedly holding discussions with Cerner Corporation (CERN) regarding a potential takeover.
CERN vs. OMCL: Which Stock Is the Better Value Option?
by Zacks Equity Research
CERN vs. OMCL: Which Stock Is the Better Value Option?
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio. However, contraction in gross margin is a woe.